FDA Launches Year Four of Drug Speed-Up Pilot Program
Published Date: 8/28/2025
Notice
Summary
The FDA is kicking off year four of its Chemistry, Manufacturing, and Controls Development and Readiness Pilot to help drug makers speed up getting important new medicines ready for patients. This program boosts teamwork between the FDA and drug developers, using smart, science-based ways to fast-track drug testing and production. If you’re making a new drug with a fast timeline, now’s the time to apply and get extra support!
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Pilot speeds CMC readiness for sponsors
The FDA announced year four of the Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP). If you are a drug developer with a product under an investigational new drug application (IND), the pilot helps expedite chemistry, manufacturing, and controls (CMC) development based on the anticipated clinical benefit of earlier patient access.
Targets CBER and CDER regulated products
The pilot applies to products regulated by the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) that have accelerated clinical development timelines. Sponsors of biologics and drugs on accelerated timelines are the intended participants for this program.
More FDA‑sponsor communication and approaches
The pilot features increased communication between FDA and sponsors and explores science- and risk-based regulatory approaches to accelerate CMC development and readiness. That means sponsors accepted into the pilot may get extra dialogue and use of risk-based methods with FDA reviewers.
Could speed earlier patient access to drugs
The pilot is intended to facilitate expedited CMC development when there is an anticipated clinical benefit of earlier patient access to products. That means some patients may get access to new medicines sooner if their developers participate in the pilot.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in